Original articleImmunosuppression for the Uveitides
Section snippets
Treatment Target
The decision to treat an individual patient and the choice of therapy always represent risk–benefit decisions. Not every case of uveitis needs treatment. In Fuchs' uveitis syndrome (also known as “Fuchs' heterochromic iridocyclitis”), treatment appears not to have beneficial effects and typically is not given. Some 25% to 35% of patients with pars planitis have mild disease, no macular edema or other complications, and good vision, and do not need treatment; these patients maintain good vision
Oral Corticosteroids
Oral corticosteroids are critical for the initial control of ocular inflammation, even when immunosuppression is used. Studies of patients with sarcoid uveitis have shown that oral corticosteroid therapy is associated with a 93% reduction in the odds of visual impairment.28 The initial dose of prednisone should be 1 mg/kg/day up to a maximum of 60 mg/day.12, 13 Doses >60 mg/day are associated with an increased risk of ischemic necrosis of bone and should be avoided.29 After 2 to 4 weeks,
Evidence for the Effectiveness of Immunosuppression
There are a limited number of randomized clinical trials demonstrating the efficacy of immunosuppression in the treatment of the uveitides. Azathioprine was shown to be effective for Behçet disease uveitis, but 22% of treated patients had uveitis relapses.35 Cyclosporine was superior to colchicine (which is ineffective for uveitis) for Behçet disease, but only 48% of patients on cyclosporine had good control of the uveitis.36 In a small single-center, randomized trial, cyclosporine was
Conventional Immunosuppressive Drugs
Conventional immunosuppressive drugs are classified as antimetabolites, calcineurin inhibitors, or alkylating agents (Table 3).13 The antimetabolites used most often are azathioprine (Imuran, Prometheus Labs, Inc, San Diego, CA), methotrexate (Rheumatrex, Dava Pharmaceuticals, Inc, Newark, DE, and others), and mycophenolate (Cellcept, Genentech, Inc, San Francisco, CA). The calcineurin inhibitors are cyclosporine (Neoral, Novartis Pharmaceuticals Corp, New York, NY) and tacrolimus (Prograf,
Remission Induction
The SITE Cohort Study suggested that sustained, drug-free remissions (i.e., inactive disease off all treatment) were uncommon with nonalkylating agent immunosuppression. In intermediate uveitis, the incidence of a sustained, drug-free remission was 0.089/PY.55 For nonalkylating agent conventional immunosuppressive drugs, the estimated remission incidence was <0.10/PY for each drug.43, 44, 45, 46 In JIA uveitis, the median time to a drug-free remission is approximately 10 years for mild disease;
Safety of Immunosuppression
The MUST Trial and Follow-up Study evaluated the safety of systemic therapy for the uveitides.27, 58, 59, 60, 61, 62 The trial randomized patients with noninfectious, intermediate, posterior, and panuveitides to treatment with the fluocinolone acetonide implant (Retisert, Bausch & Lomb, Rochester, NY) or systemic therapy with oral corticosteroids and immunosuppression. The fluocinolone acetonide implant is surgically placed in the eye and releases corticosteroids over a period of 2.5 to 3 years.
Biologics for the Uveitides
Biologics have transformed the field of rheumatology and are widely used. In uveitis, most of the data on biologics are on the use of agents directed against tumor necrosis factor (TNF)-α and involve infliximab (Remicade, Janssen Biotech, Inc, Titusville, NJ), a chimeric monoclonal antibody to TNF-α given as an intravenous infusion, or adalimumab (Humira, AbbVie, Inc, North Chicago, IL), a fully human monoclonal antibody given every other week as a subcutaneous injection.72, 73, 74, 75, 76
References (96)
- et al.
Approach to the diagnosis of the uveitides
Am J Ophthalmol
(2013) - et al.
Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study
Ophthalmology
(2004) - et al.
Understanding uveitis: the impact of research on visual outcomes
Prog Retin Eye Res
(2011) - et al.
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
Am J Ophthalmol
(2000) - et al.
Pars planitis: clinical features and class II HLA associations
Ophthalmology
(1999) - et al.
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study
Ophthalmology
(2013) - et al.
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity
Am J Ophthalmol
(2008) - et al.
Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease
Am J Ophthalmol
(2002) - et al.
Prognosticators for visual outcome in sarcoid uveitis
Ophthalmology
(1996) - et al.
Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone
Lancet
(1987)
A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States
Ophthalmology
Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's disease
Lancet
Randomized double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis
Am J Ophthalmol
A randomized clinical trial comparing methotrexate and mycophenolate mofetil for non-infectious uveitis
Ophthalmology
Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity
Ophthalmology
Cyclosporine for ocular inflammatory diseases
Ophthalmology
Cyclophosphamide for ocular inflammatory diseases
Ophthalmology
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation
Ophthalmology
Success with single agent immunosuppression for multifocal choroidopathies
Am J Ophthalmol
Successful treatment of serpiginous choroiditis with alkylating agents
Ophthalmology
Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation
Ophthalmology
Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis
Am J Ophthalmol
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study
Ophthalmology
Outcome of treatment of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) Trial 2-year results
Ophthalmology
Chlorambucil and malignancy
Ophthalmology
Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study
Ophthalmology
Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients
Ophthalmology
Behçet disease: visual prognosis and factors influencing the development of visual loss
Am J Ophthalmol
Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up
Ophthalmology
Infliximab for chronic cystoid macular edema associated with uveitis
Am J Ophthalmol
Adalimumab for the prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo-controlled phase 3 trial
Lancet
Secukinumab in the treatment of non-infectious uveitis: results of three randomized, controlled clinical trials
Ophthalmology
Prevalence of non-infectious uveitis in the United States: a claims-based analysis
JAMA Ophthalmol
Prevalence of the uveitides in the United States
JAMA Ophthalmol
Epidemiology of uveitis
Ophthalmic Epidemiol
The natural history of uveitis
Int Ophthalmol
The possible impact of uveitis in blindness: a literature survey
Br J Ophthalmol
Causes and frequency of blindness in patients with intraocular inflammatory disease
Br J Ophthalmol
Direct and indirect resource use, healthcare costs and workforce absence in patients with non-infectious intermediate, posterior, or panuveitis
Acta Ophthalmologica
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
Am J Ophthalmol
Treatment of ocular inflammation
Ocul Immunol Inflamm
Pars planitis: a 20-year study of incidence, clinical features, and outcomes
Am J Ophthalmol
Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis
Am J Ophthalmol
Fundus autofluorescence imaging of the white dot syndromes
Arch Ophthalmol
Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging
Retina
Fundus autofluorescence imaging in multifocal choroiditis: beyond the spots
Ocular Immunol Inflamm
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss
Am J Ophthalmol
Loss of visual field among patients with birdshot chorioretinopathy
Am J Ophthalmol
Cited by (124)
Immunomodulatory Treatment Versus Systemic Steroids in Inflammatory Choroidal Neovascularization Secondary to Idiopathic Multifocal Choroiditis
2024, American Journal of OphthalmologyUpdate on the systemic management of noninfectious uveitis in children and adolescents
2024, Survey of OphthalmologyUveitis and immunosuppressive treatment: Experience in a multidisciplinary uveitis unit
2023, Revista Colombiana de Reumatologia
Financial Disclosure(s): The author has no proprietary or commercial interest in any materials discussed in this article.
Supported in part by Cooperative Agreement U10 EY014655 to the Icahn School of Medicine from the National Eye Institute, National Institutes of Health, Bethesda, Maryland. Bausch & Lomb, Inc, donated a limited supply of fluocinolone acetonide implants to the Multicenter Uveitis Steroid Treatment (MUST) Trial.
Off-label Drug Use: azathioprine, methotrexate, mycophenolate, cyclosporine, tacrolimus, cyclophosphamide, chlorambucil, infliximab, abatacept, tocilizumab, and rituximab.
HUMAN SUBJECTS: This article discusses multiple human studies, all of which had IRB approval, and followed the tenets of the Declaration of Helsinki.
Author Contributions:
Conception and design: Jabs
Data collection: Jabs
Analysis and interpretation: Jabs
Obtained funding: Not applicable
Overall responsibility: Jabs